Therefore, further subcategorization of EGFR-mutated NSCLC that can be used to predict responses to combined EGFR TKI and VEGF inhibitor therapy is needed if the development of osimertinib and VEGF inhibitor combination therapy is to continue. Here, VEGFA is linked to non-small cell lung carcinoma.